In this CME/CE/CPE-certified activity, Anna F. Farago, MD, PhD; Matthew D. Hellmann, MD; and Taofeek K. Owonikoko, MD, PhD, discuss practical considerations regarding the use of immune checkpoint inhibitors and antibody–drug conjugates in the treatment of patients with small-cell lung cancer.
In this downloadable slideset, Anna F. Farago, MD, PhD; Matthew D. Hellmann, MD; and Taofeek K. Owonikoko, MD, PhD, review key data on immunotherapy and antibody–drug conjugates in SCLC.
Second-line therapy options are limited for advanced SCLC. Are immunotherapy regimens safe and efficacious enough to consider for this patient population?
Rova-T achieved high response rates in a phase I clinical trial of patients with recurrent SCLC, particularly those with high DLL3 expression. Here’s my take on the promise of Rova T in this patient population.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.